Summary

Overview
Global Gaucher Disease Therapeutics Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing with a CAGR of XX % during the forecast period 2024-2031.
Gaucher disease is a rare genetic disorder characterized by the deficiency of an enzyme called glucocerebrosidase. This enzyme normally breaks down a fatty substance called glucocerebroside, which accumulates primarily in the spleen, liver, and bone marrow of affected individuals. Treatment for Gaucher disease often involves enzyme replacement therapy (ERT), where the missing enzyme is replaced with a synthetic version. This can help alleviate symptoms and prevent complications. Additionally, supportive care such as pain management and physical therapy may be recommended.
Gaucher disease is an autosomal recessive genetic disorder caused by mutations in the GBA gene, which encodes the enzyme glucocerebrosidase. Individuals with Gaucher disease inherit two defective copies of the GBA gene, one from each parent. Genetic testing can identify mutations in the GBA gene, aiding in diagnosis and family counseling.
Market Dynamics: Drivers and Restraints
Rising advancements in diagnostic technologies
Technological advancements, such as improved genetic testing techniques and biomarker identification, facilitate accurate and early diagnosis of Gaucher disease. This leads to an increased demand for therapeutics to manage the condition. Technological advancements have led to the development of more sensitive and specific genetic testing techniques for Gaucher disease.
Next-generation sequencing (NGS) technologies, such as whole-exome sequencing (WES) and whole-genome sequencing (WGS), enable comprehensive analysis of the GBA gene and other relevant genetic loci associated with Gaucher disease. These advanced genetic tests can identify disease-causing mutations with high accuracy, allowing for precise diagnosis and personalized treatment strategies. Advances in biomarker discovery and validation have facilitated the identification of novel biomarkers associated with Gaucher disease.
Biomarkers such as chitotriosidase and CCL18 have been shown to correlate with disease severity and response to treatment. High-throughput screening techniques, such as proteomics and metabolomics, enable the identification and validation of biomarkers that can aid in diagnosis, prognosis, and monitoring of disease progression. The availability of reliable biomarkers enhances the diagnostic accuracy and monitoring of Gaucher disease, driving the demand for therapeutics.
Market Dynamics: Restraint
Potential side effects and safety concerns
Side effects or safety concerns associated with Gaucher disease therapeutics, such as enzyme replacement therapy (ERT) or substrate reduction therapy (SRT), can affect patient adherence to treatment regimens. For instance, if patients experience infusion-related reactions with ERT or gastrointestinal side effects with SRT, they may be less likely to adhere to prescribed treatment schedules. Poor adherence to therapy can lead to suboptimal disease management, disease progression, and potentially worsened outcomes, thereby restraining market growth.
Gaucher disease therapeutics may need to be used with caution in certain patient populations, such as pregnant women, pediatric patients, and individuals with pre-existing medical conditions. Safety considerations related to pregnancy, lactation, pediatric dosing, and comorbidities may restrict the use of certain therapies in these populations, limiting market uptake and growth.
Segment Analysis
The global gaucher disease therapeutics market is segmented based on disease type, therapy type, route of administration, end-user and region.
The type -1 from the disease type segment accounted for approximately 31.09% of share
The development and availability of effective treatments, such as enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), have expanded treatment options for individuals with Type 1 Gaucher disease. These therapies can alleviate symptoms, improve quality of life, and reduce complications associated with organ involvement, leading to increased demand and growth of the Type 1 segment in the therapeutics market.
With advancements in medical care and treatment, individuals with Type 1 Gaucher disease are experiencing longer life expectancies compared to previous decades. Improved management of symptoms and complications, coupled with early initiation of therapy, contribute to better outcomes and survival rates in this patient population.
The increasing prevalence of Type 1 Gaucher disease due to longer life expectancy contributes to the growth of this segment in the therapeutics market. The rise of the Type 1 (non-neuronopathic) segment in the Gaucher disease therapeutics market is driven by increased awareness and diagnosis, expanded treatment options, longer life expectancy, genetic counseling initiatives, and patient advocacy efforts.
Geographical Analysis
North America accounted for approximately 41.04% of the market share in 2022
North America has a relatively higher prevalence of Gaucher disease compared to other regions. This higher prevalence is partly due to better awareness, advanced diagnostic capabilities, and widespread access to healthcare services. As a result, there is a larger patient pool in North America requiring treatment for Gaucher disease, which drives market growth in the region.
For instance, according to a report published by NORD in March 2020, the U.S. alone has approximately 6000 people living with Gaucher disease. Organizations such as the National Gaucher Foundation of the U.S. and the National Gaucher Foundation of Canada are spreading awareness among people about Gaucher disease.
Additionally, North America boasts advanced healthcare infrastructure, including well-established healthcare systems, specialized treatment centers, and academic medical institutions. This infrastructure supports early diagnosis, optimal disease management, and access to cutting-edge therapeutics for individuals with Gaucher disease. The availability of specialized healthcare facilities and expertise contributes to the growth of the Gaucher disease therapeutics market in the region.
COVID-19 Impact Analysis
The pandemic has resulted in a wide range of challenges to the delivery of medical care, the nature of which has varied, depending on a patient's underlying disorder. As the early understanding of the pathophysiology evolved, researchers demonstrated that as part of enhancing its survival and infectivity, the SARS-CoV-2 particles remain infective by exiting cells through a process where lysosomes get de-acidified in coronavirus-infected cells, resulting in a marked disruption of lysosomal enzyme activities.
During the early phase of the pandemic, a group of Gaucher investigators together identified potential Sars-CoV-2-related management challenges specifically for the Gaucher patient population, providing some suggestions and identifying concerns requiring additional research. The economic repercussions of the COVID-19 pandemic, including job losses, income reductions, and healthcare budget constraints, may have affected patient access to Gaucher disease therapeutics.
Market Segmentation
By Disease Type
• Type 1 (non-neuronopathic)
• Type 2 (acute neuronopathic)
• Type 3 (chronic neuronopathic)
By Therapy Type
• Enzyme replacement therapy (ERT)
• Substrate reduction therapy (SRT)
• Chaperone therapy
By Route of Administration
• Intravenous (IV)
• Oral
• Intrathecal (IT)
By End-User
• Hospitals
• Specialty clinics
• Research Institutions
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Sanofi, Protalix BioTherapeutics, Inc, Takeda Pharmaceutical, Pfizer Inc, Actelion Pharmaceuticals, Amicus Therapeutics, Inc, Centogene AG, JCR Pharmaceuticals Co., Ltd, Adienne Pharma & Biotech SA, AceLink Therapeutics Inc among others.
Why Purchase the Report?
• To visualize the global Gaucher disease therapeutics market segmentation based on disease type, therapy type, route of administration, end-user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Gaucher disease therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Gaucher disease therapeutics market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Therapy Type
3.3. Snippet by Route of Administration
3.4. Snippet by End-User
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising advancements in diagnostic technologies
4.1.1.2. Increasing prevalence of Gaucher disease
4.2. Restraints
4.2.1.1. Potential side effects and safety concerns
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Type 1 (non-neuronopathic) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Type 2 (acute neuronopathic)
7.4. Type 3 (chronic neuronopathic)
8. By Therapy Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
8.1.2. Market Attractiveness Index, By Therapy Type
8.2. Enzyme replacement therapy (ERT) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Substrate reduction therapy (SRT)
8.4. Chaperone therapy
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Intravenous (IV) *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral
9.4. Intrathecal (IT)
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals
10.4. Specialty clinics
10.5. Research Institutions
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. South Korea
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Sanofi *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Protalix BioTherapeutics, Inc
13.3. Takeda Pharmaceutical
13.4. Pfizer Inc
13.5. Actelion Pharmaceuticals
13.6. Amicus Therapeutics, Inc
13.7. Centogene AG
13.8. JCR Pharmaceuticals Co., Ltd
13.9. Adienne Pharma & Biotech SA
13.10. AceLink Therapeutics Inc
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us